Zobrazeno 1 - 1
of 1
pro vyhledávání: '"EGFR mutant lung cancer therapy"'
Autor:
Daniel G. Tenen, Fhu Chee Wai, Elena Levantini, Thomas C. Putti, Wanjin Hong, Eva Csizmadia, Jeff Settleman, John G. Clohessy, Margaret P. Quinlan, Chen Xie, Azhar Ali, Tan Min Chin, Ellen P S Man, Boon Cher Goh, Seow-Ching Wan, Gandhi T K Boopathy, Yan Shan Ong
Publikováno v:
Theranostics
Theranostics 10 (2020): 2727–2743. doi:10.7150/thno.38729
info:cnr-pdr/source/autori:Chin T.-M.; Boopathy G.T.K.; Man E.P.S.; Clohessy J.G.; Csizmadia E.; Quinlan M.P.; Putti T.; Wan S.-C.; Xie C.; Ali A.; Wai F.C.; Ong Y.S.; Goh B.-C.; Settleman J.; Hong W.; Levantini E.; Tenen D.G./titolo:Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors/doi:10.7150%2Fthno.38729/rivista:Theranostics/anno:2020/pagina_da:2727/pagina_a:2743/intervallo_pagine:2727–2743/volume:10
Theranostics 10 (2020): 2727–2743. doi:10.7150/thno.38729
info:cnr-pdr/source/autori:Chin T.-M.; Boopathy G.T.K.; Man E.P.S.; Clohessy J.G.; Csizmadia E.; Quinlan M.P.; Putti T.; Wan S.-C.; Xie C.; Ali A.; Wai F.C.; Ong Y.S.; Goh B.-C.; Settleman J.; Hong W.; Levantini E.; Tenen D.G./titolo:Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors/doi:10.7150%2Fthno.38729/rivista:Theranostics/anno:2020/pagina_da:2727/pagina_a:2743/intervallo_pagine:2727–2743/volume:10
Oncogene-addicted cancers are predominantly driven by specific oncogenic pathways and display initial exquisite sensitivity to designer therapies, but eventually become refractory to treatments. Clear understanding of lung tumorigenic mechanisms is e